Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
OBX · Why this verdict
Why Obsidian Therapeutics (OBX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Obsidian Therapeutics shows a strong balance sheet and ample liquidity, but a persistent earnings-miss pattern, a speculative no-edge classification, and a current price-data outage keep the setup unactionable and position sizing capped near zero.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A live pricing data outage (no price returned by the upstream feed for this run) currently prevents any entry, target, or stop-loss calculation for Obsidian. Warnings | Price data availability should resume within the next 1-2 refresh cycles, restoring the ability to compute a live trade setup. | →Stable |
| CounterA persistent data outage could reflect a genuinely illiquid or delisting-adjacent security rather than a transient feed issue. | ||
Obsidian carries a very strong liquidity position, with a current-ratio quality-component score of 8.8, giving the clinical-stage biotech meaningful balance-sheet runway. Current ratio | The current-ratio component score should stay at or above 7.0 over the next 12 months without a sudden liquidity drawdown. | →Stable |
| CounterAs a clinical-stage biotech with no revenue growth data provided in this bundle, cash reserves could deplete quickly if trial costs accelerate. | ||
Obsidian has missed consensus estimates in 3 of the last 4 quarters with an average surprise of -10.28%, a track record that signals estimate-calibration or execution risk. Avg surprise pct | The beat count should rise to at least 2 of the trailing 4 reported quarters over the next year for this risk to meaningfully ease. | ↑Improving |
| CounterLoss-making clinical-stage biotechs routinely post volatile, low-signal EPS surprises that don't reflect commercial execution quality. | ||
The engine classifies Obsidian as a speculative-suitability name in a binary biotech industry with no identifiable market edge, which has driven position sizing down to an avoid-level allocation. Position-sizing math | Suggested position sizing should exceed 1.0% of portfolio, up from the current 0.5%, once a clear edge and adequate asymmetry are established. | — |
| CounterSpeculative-tier sizing caps are a structural feature of pre-revenue, binary-outcome biotech names and may persist regardless of underlying fundamentals. | ||
A live pricing data outage (no price returned by the upstream feed for this run) currently prevents any entry, target, or stop-loss calculation for Obsidian.
→StableWarnings
- Expectation
- Price data availability should resume within the next 1-2 refresh cycles, restoring the ability to compute a live trade setup.
CounterA persistent data outage could reflect a genuinely illiquid or delisting-adjacent security rather than a transient feed issue.
Obsidian carries a very strong liquidity position, with a current-ratio quality-component score of 8.8, giving the clinical-stage biotech meaningful balance-sheet runway.
→StableCurrent ratio
- Expectation
- The current-ratio component score should stay at or above 7.0 over the next 12 months without a sudden liquidity drawdown.
CounterAs a clinical-stage biotech with no revenue growth data provided in this bundle, cash reserves could deplete quickly if trial costs accelerate.
Obsidian has missed consensus estimates in 3 of the last 4 quarters with an average surprise of -10.28%, a track record that signals estimate-calibration or execution risk.
↑ImprovingAvg surprise pct
- Expectation
- The beat count should rise to at least 2 of the trailing 4 reported quarters over the next year for this risk to meaningfully ease.
CounterLoss-making clinical-stage biotechs routinely post volatile, low-signal EPS surprises that don't reflect commercial execution quality.
The engine classifies Obsidian as a speculative-suitability name in a binary biotech industry with no identifiable market edge, which has driven position sizing down to an avoid-level allocation.
—Position-sizing math
- Expectation
- Suggested position sizing should exceed 1.0% of portfolio, up from the current 0.5%, once a clear edge and adequate asymmetry are established.
CounterSpeculative-tier sizing caps are a structural feature of pre-revenue, binary-outcome biotech names and may persist regardless of underlying fundamentals.
Per-dimension breakdown
Quality
3.0/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.9 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 1.3 |
| OBV | 1.0 |
| MA position | 3.5 |
| Volume | 1.1 |
- ▸Volume distribution (falling OBV)
Sentiment
8.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 6.8 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Light analyst coverage (3.0) — signal dampened
- ▸Analyst upside: 191%
Insider
5.0/10data confidence 25%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.7 |
| 52w position | 0.0 |
Risk (lower is worse)
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 10.0 |
| volatility | 0.0 |
| beta | 1.3 |
| debt equity | 9.6 |
Catalyst
3.6/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 3.3 |
| surprise avg | 2.6 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:9.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.1<4.5
Warning (0)
none
Reward-to-Risk
9.81
Upside
+147.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Drawdown -73% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.1<4.5 outcome against Value at 9.0 and asymmetric R:R of 9.81.
The strongest dimensions are Value at 9.0, Sentiment at 8.3, and Technical at 6.6; the weakest are Momentum at 2.1, Quality at 3.0, and Catalyst at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 9.81 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Balance Sheet Liquidity
Trip ifCurrent-ratio quality-component score falls below 5.0 from the current 8.8.
- P2Persistent Earnings Miss Pattern
Trip ifBeat count rises above 2 of the trailing 4 reported quarters, reversing the current 1-beat/3-miss pattern.
- P3Speculative Tier No Edge Classification
Trip ifSuggested position sizing exceeds 1.0% of portfolio, up from the current 0.5%.
- P4Price Data Outage Blocks Trade Setup
Trip ifCurrent price data stays below $0.01 for more than 2 consecutive refresh cycles.